Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: icanpickem who started this subject	10/22/2003 8:18:05 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 3044

Angiomax price increase was 9% vs I at 5.2% 07:51 ET MDCO The Medicines Co upgraded at WR Hambrecht (24.66) WR Hambrecht upgrades to Buy from Hold based on expectations for strong sales growth for Angiomax in Q4 and Q1 driven by increased unit demand and a 9% price increase in June; firm says new manufacturing efficiencies should boost profitability over the same period, making the upcoming qtr the first qtr of sustained profitability, and firm believes that if the one-year data for Replace-2 at the AHA meeting in Nov replicates the trends observed at 30 days and six months, they would expect continued sales growth and stock appreciation towards their $32 target.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next